Neuropace, Inc. - Common Stock — Filings & Documents (NASDAQ:NPCE) — Page 8 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2021

Current report, 26 Apr 2021

Neuropace Inc current report, 26 April 2021

Quarterly report, Q1 FY2021

Neuropace Inc quarterly report, Q1 FY2021

1
2
3
4
5
6
7
8

News

Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now